Skip to main content
TipRanks
Go Ultimate75% OFF

Hypha Labs (FUNI) AI Stock Analysis

17 Followers
FUNI

Hypha Labs

(Other OTC:FUNI)

Select Model
Rating:41Neutral
Price Target:$0.03â–²(1291.30% Upside)
Action:reiterated
Date:02/18/26

The score is primarily held down by very weak financial performance (zero revenue, sizable losses, negative equity, and continued cash burn). Technical indicators also lean bearish (negative MACD, RSI in the mid-30s, and price below short-term moving averages). Valuation provides little support given the negative P/E and lack of dividend yield.

Positive Factors
Improving cash-flow trendTTM free cash flow remains negative but shows improvement versus the prior year, indicating management has reduced burn. That trend, if sustained, lowers near-term refinancing pressure and extends runway, offering a more durable path to stability while revenue remains absent.
Negative Factors
Zero revenue run-rateNo reported revenue in the trailing period indicates the company lacks recurring sales or commercial traction. Absent material product commercialization, the firm cannot organically fund operations, making sustained external financing or a strategic pivot necessary for long-term viability.

Hypha Labs (FUNI) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%FUNI-57.69%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$327.79K
Dividend Yield
―
Average Volume (3M)
391.26K
Price to Earnings (P/E)
-0.2
Beta (1Y)
0.33
Revenue Growth
―
EPS Growth
47.23%
Country
US
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Hypha Labs Business Overview & Revenue Model

Company Description

Hypha Labs, Inc. focuses on the investigation, development, and market release of bioreactor systems across the United States. Their key offering is the Hypha Micropearl bioreactor, a specialized household device engineered to rapidly cultivate benef...

How the Company Makes Money

null

Hypha Labs Financial Statement Overview

Summary

Financial performance is extremely weak: TTM shows zero revenue, large operating and net losses, negative equity, and ongoing negative operating and free cash flow. Reduced cash burn versus the prior year is a modest positive, but overall results indicate high funding and execution risk.

Income Statement

12Very Negative

Balance Sheet

10Very Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Dec 2021
Income Statement
Total Revenue00002.70M2.50M
Gross Profit-23.96K0001.07M715.16K
EBITDA-1.47M-2.95M-1.37M-58.24K-1.73M-249.00K
Net Income-1.91M-3.10M-785.00K246.77K-2.06M-687.00K
Balance Sheet
Total Assets68.33K409.22K493.81K1.41M1.34M1.89M
Cash, Cash Equivalents and Short-Term Investments5,11038.12K91.17K271.01K56.17K295.93K
Total Debt1.79M1.65M1.14M2.29M2.35M2.79M
Total Liabilities3.16M2.51M1.42M3.28M4.08M2.94M
Stockholders Equity-3.09M-2.10M-926.69K-1.87M-2.41M-1.05M
Cash Flow
Free Cash Flow-599.29K-412.94K-1.42M112.52K-202.51K-192.17K
Operating Cash Flow-568.05K-379.98K-1.39M112.53K-184.79K-135.97K
Investing Cash Flow-31.24K-32.97K2.15M263.33K-660.37K-286.21K
Financing Cash Flow457.21K359.89K-1.28M-161.02K605.39K635.36K

Hypha Labs Risk Analysis

Hypha Labs disclosed 32 risk factors in its most recent earnings report. Hypha Labs reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We have outstanding shares of Series C Preferred stock held by our sole executive officer that will enable him to control a majority of the total voting power of the Company.Q3, 2024
2.We plan to increase the amount of authorized shares of our common stock and our preferred stock.Q3, 2024
3.Our limited operating history in our current business makes it difficult to evaluate our current business and future prospects and the risk of your investment.Q3, 2024

Hypha Labs Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FUNI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PRPOPRPO60Neutral$39.68M-36.61-7.84%―21.76%22.97%
INBSINBS54Neutral$5.84M-0.26-146.09%―36.55%60.09%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BIAFBIAF42Neutral$4.00M-0.04-331.02%―-18.47%87.82%
FUNIFUNI41Neutral$475.30K-0.1673.84%――47.23%
ISPCISPC40Underperform$1.66M-0.01-524.37%―-92.11%86.78%
TRIBTRIB38Underperform$3.93M-0.1348.72%―-13.28%39.65%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%FUNITRIBPRPOINBSISPCBIAFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FUNI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FUNIHypha Labs, Inc.0.01-0.01-56.00%
TRIBTrinity Biotech6.10-18.47-75.17%
PRPOPrecipio22.131.105.23%
INBSIntelligent Bio Solutions Inc.1.76-5.16-74.57%
ISPCIspecimen Inc0.66-22.55-97.17%
BIAFbioAffinity Technologies, Inc.2.20-21.50-90.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Feb 18, 2026